Latest News
- Alkermes Reports Third Quarter Fiscal 2010 Financial Results Continue Reading »
- Alkermes Unveils Long-Acting Injectable Proprietary Platform for Treatment of Schizophrenia and Other CNS Disorders Continue Reading »
- Alkermes' Corporate Presentation to be Webcast at the BIO CEO & Investor Conference Continue Reading »
Research Spotlight
-
Our approach to research and development is unparalleled.
